Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Organisation › Details

AiCuris Anti-infective Cures GmbH

AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs against infectious diseases. The Company's majority investor is SANTO Holding. The Company is developing drugs for the treatment of viruses such as human cytomegalovirus (HCMV), herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, (multidrug)-resistant hospital-treated pathogens. In 2012, AiCuris signed a license agreement with Merck & Co (MSD), one of the largest agreements of its kind in the European biotech industry. The agreement covers the development and commercialization of novel drug candidates against HCMV, including letermovir, which met the primary endpoint in a pivotal phase 3 clinical trial in patients undergoing bone marrow transplantation. *

 

Period Start 2014-12-19 splitoff
  Group STRÜNGMANN Group (family Strüngmann)
  Predecessor AiCuris GmbH & Co. KG
Product Industry anti-infective drug
Persons Person Zimmermann, Holger (AiCuris 201609 CEO before CSO)
  Person 2 Schmoll, Holger (AiCuris 2010 CFO)
     
Region Region Wuppertal
  Country Germany
  Street 475 Friedrich-Ebert-Str.
  City 42117 Wuppertal
    Address record changed: 2016-08-29
     
Basic data Employees C: 51 to 100 (2012-10-06)
     
    * Document for �About Section�: AiCuris Anti-infective Cures GmbH. (10/24/17). "Press Release: AiCuris AIC649 Showed Potential for Functional Cure in Woodchuck Model for Chronic Hepatitis B". Wuppertal.
     
   
Record changed: 2018-10-31

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for STRÜNGMANN Group (family Strüngmann)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top